Avenzo Therapeutics announces FDA clearance of Investigational New Drug application for AVZO-103, a potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate

CAR-T Digest - August 2020

Weekly Digest - September 2025

02 September 2025: Avenzo Therapeutics announces FDA clearance of Investigational New Drug application for AVZO-103, a potential best-in-class Nectin4/TROP2 bispecific antibody-drug conjugate

Avenzo Therapeutics received FDA clearance of its IND for AVZO-103, a Nectin4/TROP2 bispecific antibody-drug conjugate, and exercised its exclusive option from VelaVigo for global rights outside Greater China
The company plans to launch a Phase 1/2 first-in-human clinical trial this year, with Phase 1 evaluating safety, tolerability, and preliminary activity as monotherapy and in combination regimens
AVZO-103 is designed as a potential best-in-class ADC to target cancers co-expressing Nectin4 and TROP2, aiming to enhance tumor cell killing while sparing normal tissue
This IND marks Avenzo’s third clearance in 2025, reflecting the strong productivity of its R&D pipeline
The initial clinical focus includes advanced solid tumors, particularly cancers like urothelial cancer with high co-expression of Nectin4 and TROP2